AstraZeneca to Resume Expansion of Cambridge R&D Site After US-UK Trade Deal Boosts UK Drug Spending
AstraZeneca announced it will restart the expansion of its research and development facility in Cambridge, United Kingdom. The move marks the first R&D project to be revived since the recent United States‑United Kingdom trade agreement.
The trade deal includes provisions aimed at increasing UK spending on medicines, creating a more favorable environment for pharmaceutical investment. By lifting financial constraints, the agreement encourages companies like AstraZeneca to grow their UK operations.
The Pharmalittle newsletter also highlighted other industry developments, including a Supreme Court hearing on the use of “skinny labels” for generic drugs and Teva Pharmaceutical’s acquisition of Emalex Biosciences to bolster its pipeline.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a Supreme Court hearing on ‘skinny labels,’ AstraZeneca U.K. expansion, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that